Rohto Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	353,385	343,725	308,625	270,840	238,664	199,646
Revenue Growth	9.67%	11.37%	13.95%	13.48%	19.54%	10.13%
Cost of Revenue	154,949	151,030	133,686	113,554	101,243	83,157
Gross Profit	198,436	192,695	174,939	157,286	137,421	116,489
Selling, General & Admin	131,906	128,132	115,521	101,377	89,859	76,435
Research & Development	13,727	13,727	14,912	13,390	11,065	8,740
Amortization of Goodwill & Intangibles	2,048	2,048	1,523	436	383	457
Operating Expenses	155,783	151,989	136,474	117,119	103,883	88,297
Operating Income	42,653	40,706	38,465	40,167	33,538	28,192
Interest Expense	-1,288	-1,284	-949	-196	-247	-248
Interest & Investment Income	2,352	5,945	1,922	2,009	2,285	751
Earnings From Equity Investments	537	92	166	-289	56	143
Currency Exchange Gain (Loss)	886	1,338	516	447	-	-
Other Non Operating Income (Expenses)	1,191	1,172	311	294	-64	245
EBT Excluding Unusual Items	46,331	47,969	40,431	42,432	35,568	29,083
Gain (Loss) on Sale of Investments	473	-907	1,896	-798	-160	-368
Gain (Loss) on Sale of Assets	-15	-	-	-	-	-
Asset Writedown	-241	-241	-175	-348	-1,338	-892
Other Unusual Items	-	-1	179	230	219	129
Pretax Income	46,548	46,820	42,331	41,516	34,289	27,952
Income Tax Expense	13,137	12,404	11,379	10,123	7,860	6,803
Earnings From Continuing Operations	33,411	34,416	30,952	31,393	26,429	21,149
Minority Interest in Earnings	-283	-169	54	-457	-52	-131
Net Income	33,128	34,247	31,006	30,936	26,377	21,018
Net Income to Common	33,128	34,247	31,006	30,936	26,377	21,018
Net Income Growth	-3.40%	10.45%	0.23%	17.28%	25.50%	25.53%
Shares Outstanding (Basic)	226	226	228	228	228	228
Shares Outstanding (Diluted)	235	235	229	229	229	229
Shares Change	2.84%	2.87%	0.04%	-	-0.00%	-
EPS (Basic)	146.61	151.56	136.11	135.60	115.62	92.13
EPS (Diluted)	140.53	145.29	135.44	135.21	115.29	91.86
EPS Growth	-6.16%	7.27%	0.17%	17.28%	25.50%	25.53%

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	-	36,294	27,837	26,266	22,451	16,983
Free Cash Flow Per Share	-	154.14	121.61	114.80	98.13	74.23
Dividend Per Share	46.000	46.000	36.000	27.000	22.000	18.000
Dividend Growth	27.78%	27.78%	33.33%	22.73%	22.22%	28.57%
Gross Margin	56.15%	56.06%	56.68%	58.07%	57.58%	58.35%
Operating Margin	12.07%	11.84%	12.46%	14.83%	14.05%	14.12%
Profit Margin	9.37%	9.96%	10.05%	11.42%	11.05%	10.53%
Free Cash Flow Margin	-	10.56%	9.02%	9.70%	9.41%	8.51%
EBITDA	61,089	58,083	51,608	48,854	41,339	35,865
EBITDA Margin	17.29%	16.90%	16.72%	18.04%	17.32%	17.96%
D&A For EBITDA	18,436	17,377	13,143	8,687	7,801	7,673
EBIT	42,653	40,706	38,465	40,167	33,538	28,192
EBIT Margin	12.07%	11.84%	12.46%	14.83%	14.05%	14.12%
Effective Tax Rate	28.22%	26.49%	26.88%	24.38%	22.92%	24.34%
Advertising Expenses	-	62,602	57,506	54,219	46,467	38,114